Du är här


Novo Nordisk A/S: Novo Nordisk increased operating profit in local currencies by 15% in the first quarter of 2014

7% sales growth in local currencies driven by Levemir®and Victoza®

Sales increased by 7% in local currencies and by 2% in Danish kroner to DKK
20.3 billion.

* Sales of modern insulin increased by 10% (4% in Danish kroner).
* Sales of Victoza® increased by 13% (9% in Danish kroner).
* Sales in North America increased by 7% (3% in Danish kroner).
* Sales in International Operations increased by 12% (decreased by 2% in
Danish kroner).
* Sales in Region China increased by 18% (15% in Danish kroner).

Gross margin improved by 1.1 percentage points in Danish kroner to 83.0%
driven by a favourable price development as well as a positive impact from
productivity and product mix.

Operating profit increased by 15% in local currencies and by 6% in Danish
kroner to DKK 8.0 billion.

Net profit increased by 8% to DKK 6.5 billion. Diluted earnings per share
increased by 10% to DKK 2.43.

The roll-out of Tresiba® (insulin degludec), the once-daily new-generation
insulin with an ultra-long duration of action, is progressing. In the first
countries to launch Tresiba® with reimbursement on a similar level as insulin
glargine, it now represents between 10% and 17% of the basal insulin market
measured in monthly value market share.

Recruitment for the cardiovascular outcomes trial for Tresiba®, DEVOTE, is
progressing ahead of plans and Novo Nordisk now expects to have sufficient
data to support an interim analysis mid-2015.

For 2014, sales growth measured in local currencies is now expected to be
7-10%, whereas expected operating profit growth measured in local currencies
is maintained at around 10%.

Lars Rebien Sørensen, CEO: "We are pleased to reiterate our expectations to
operating profit growth for 2014 despite a challenging start of the year and
a lower outlook for sales growth. We are encouraged by the performance of
Tresiba® in key markets and by the rapid recruitment into the DEVOTE study,
which enables us to shorten the timeline for the interim analysis and a
potential US launch."

Contacts for further information

|Media: |
|Mike Rulis +45 4442 3573 mike@novonordisk.com |
|Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com |
|Investors: |
|Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com |
|Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com |
|Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com |
|Daniel Bohsen +45 3079 6376 dabo@novonordisk.com |
|Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com |
Company announcement No 29 / 2014

Company announcement No 29 / 2014


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.